CEL-SCI (FRA:LSRM) Total Liabilities : €13.74 Mil (As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is CEL-SCI Total Liabilities?

CEL-SCI's Total Liabilities for the quarter that ended in Dec. 2024 was €13.74 Mil.

CEL-SCI's quarterly Total Liabilities declined from Jun. 2024 (€14.49 Mil) to Sep. 2024 (€12.73 Mil) but then increased from Sep. 2024 (€12.73 Mil) to Dec. 2024 (€13.74 Mil).

CEL-SCI's annual Total Liabilities declined from Sep. 2022 (€18.54 Mil) to Sep. 2023 (€16.22 Mil) and declined from Sep. 2023 (€16.22 Mil) to Sep. 2024 (€12.73 Mil).

CEL-SCI Total Liabilities Historical Data

The historical data trend for CEL-SCI's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI Total Liabilities Chart

CEL-SCI Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Total Liabilities

Get a 7-Day Free Trial

17.67

16.44

18.54

16.22

12.73

CEL-SCI Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															14.73	14.48	14.49	12.73	13.74

CEL-SCI Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CEL-SCI's Total Liabilities for the fiscal year that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4.159	+	(8.455	+	0.113
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	12.73

Total Liabilities	=	Total Assets (A: Sep. 2024 )	-	Total Equity (A: Sep. 2024 )
	=	24.32	-	11.593
	=	12.73

CEL-SCI's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.233	+	(8.391	+	0.118
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	13.74

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	24.543	-	10.8
	=	13.74

CEL-SCI Total Liabilities Related Terms

Thank you for viewing the detailed overview of CEL-SCI's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CEL-SCI Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (FRA:LSRM) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

CVM:USA LSRM:Germany

Address

8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182

Website

https://www.cel-sci.com

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

CEL-SCI Headlines

No Headlines